1523-4681/asset/olbannerleft.gif?v=1&s=d7e4c0e37904a489128d3a4e58ba94214db307a9)
1523-4681/asset/olbannerright.gif?v=1&s=854ee0e4d351ead9faaca8bfab3e50b1c7c9d03d)
Original Article
You have full text access to this OnlineOpen article
ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation
Article first published online: 14 DEC 2009
DOI: 10.1359/jbmr.091110
Copyright © 2010 American Society for Bone and Mineral Research
Additional Information
How to Cite
Dinther, M. v., Visser, N., de Gorter, D. J., Doorn, J., Goumans, M.-J., de Boer, J. and ten Dijke, P. (2010), ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res, 25: 1208–1215. doi: 10.1359/jbmr.091110
Publication History
- Issue published online: 27 MAY 2010
- Article first published online: 14 DEC 2009
- Accepted manuscript online: 27 JAN 2010 12:00AM EST
- Manuscript Accepted: 20 NOV 2009
- Manuscript Revised: 12 OCT 2009
- Manuscript Received: 5 AUG 2009
References
- 1, , , et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008; 22: 191–205.
- 2, , , et al. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab. 2008; 26: 521–530.
- 3, , , et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006; 38: 525–527.
- 4, , , et al. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun. 2008; 377: 905–909.
- 5. Bone: formation by autoinduction. Science. 1965; 150: 893–899.
- 6, . Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc Natl Acad Sci U S A. 1981; 78: 7599–7603.
- 7, , , et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242: 1528–1534.
- 8, , , et al. OP-1 cDNA encodes an osteogenic protein in the TGF-β family. EMBO J. 1990; 9: 2085–2093.
- 9, , , et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res. 2008; 102: 914–922.
- 10, . A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol. 2009; 10: 20.
- 11, , . Stimulation of the expression of osteogenic and chondrogenic phenotypes in vitro by osteogenin. Proc Natl Acad Sci U S A. 1989; 86: 8793–8797.
- 12, , , et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol. 1994; 127: 1755–1766.
- 13
- 14, , . Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes. J Cell Biol. 2002; 159: 135–146.
- 15, , , et al. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci U S A. 2009; 106: 12670–12675.
- 16, , , et al. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med. 1996; 335: 555–561.
- 17, , , . Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol. 2004; 165: 1107–1115.
- 18, , . BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005; 16: 251–263.
- 19, , , et al. Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol Cell Biol. 1994; 14: 944–950.
- 20, , . GS domain mutations that constitutively activate Tβ R-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 1995; 14: 2199–2208.
- 21, , , et al. The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type I receptors. Cell. 1996; 86: 435–444.
- 22, , , et al. Characterization of the interaction of FKBP12 with the transforming growth factor-β type I receptor in vivo. J Biol Chem. 1996; 271: 21687–21690.
- 23, , . Mechanism of TGFβ receptor inhibition by FKBP12. EMBO J. 1997; 16: 3866–3876.
- 24, , , . Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell. 1999; 96: 425–436.
- 25, , , et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem. 1994; 269: 16985–16988.
- 26, , , et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci. 2007; 120: 964–972.
- 27, , , et al. Expression of type I and type IB receptors for activin in midgestation mouse embryos suggests distinct functions in organogenesis. Mech Dev. 1995; 52: 109–123.
- 28, . Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord. 2006; 7: 51–65.
- 29, . Negative regulation of TGF-β receptor/Smad signal transduction. Curr Opin Cell Biol. 2007; 19: 176–184.
- 30, , , , . Gene array analysis of bone morphogenetic protein type I receptor-induced osteoblast differentiation. J Bone Miner Res. 2003; 18: 1177–1185.Direct Link:
- 31, , , , , . A comparison of the osteoinductive potential of two calcium phosphate ceramics implanted intramuscularly in goats. J Mater Sci Mater Med. 2002; 13: 1271–1275.
- 32, . Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem. 2002; 277: 4883–4891.
- 33, , , et al. The L45 loop in type I receptors for TGF-β family members is a critical determinant in specifying Smad isoform activation. FEBS Lett. 1998; 434: 83–87.
- 34, , , et al. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol. 1991; 113: 681–687.
- 35, , , . Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res. 2007; 25: 1029–1041.Direct Link:
- 36, , , et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008; 4: 33–41.
- 37, , , et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res. 2008; 23: 305–313.Direct Link:
- 38, , . Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin Orthop Relat Res. 2007; 462: 87–92.
- 39, , , et al. Gene expression profiling highlights defective myogenesis in DMD patients and a possible role for bone morphogenetic protein 4. Neurobiol Dis. 2006; 23: 228–236.